The PROfound and TRITON2 clinical trials have demonstrated the benefit of the PARP inhibitors olaparib and rucaparib for the treatment of metastatic castration-resistant prostate cancer. The study was published in the Journal of Clinical Oncology®. In some cases, you might continue treatment if your cancer gets worse and your doctor thinks this is in your best interest. Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic . Phase 3 ARIEL3 trial evaluating Rubraca ® (rucaparib) for the maintenance treatment of advanced ovarian cancer, as well as genomic characteristics of BRCA1/2 mutations among metastatic castration-resistant prostate cancer (mCRPC) patients in the Phase 2 TRITON2 trial evaluating Rubraca in mCRPC. Patients should be selected for therapy based on . Rubraca ® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone): that has spread to other parts of the body, and. NCCN Clinical Practice Guidelines in Oncology. The findings of an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with the targeted poly (ADP-ribose) polymerase inhibitor rucaparib, which recently became FDA approved. About this study. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. "Based on these results, rucaparib was granted accelerated . Initial results from the phase II TRITON2 study evaluating rucaparib in men who have progressed on an androgen receptor directed therapy and chemotherapy demonstrated confirmed radiographic and PSA responses in 44.0% and 51.1% of patients with a deleterious BRCA1/2 alteration, initially presented at ESMO 2018 During a virtual Targeted Oncology Case-Based Roundtable event, Robert Dreicer, MD, MS, MACP, faculty chair, professor of Medicine and Urology at the . The aim of this research is to find out if the study drug rucaparib leads to lowering of PSA levels in men with metastatic prostate cancer that has not yet been treated with androgen deprivation therapy (also referred to as metastatic hormone sensitive prostate cancer) and who have an inherited mutation in a gene involved in repairing DNA damage. The new prostate cancer rucaparib data in patients with pathogenic BRCA alterations (germline or somatic) presented in the manuscript by Abida et al are important for several reasons. Rucaparib is being studied in the Phase 3 TRITON3 trial for patients with BRCA mutations and ATM mutations who have progressed on AR-targeted therapy and who have not yet received chemo in the castrate-resistant setting. Prostate cancer •for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration -resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane -based chemotherapy. Caroline Seymour. They cover the use of the drugs in men whose prostate cancer has spread, or metastasized, and whose disease has stopped responding to standard hormone treatments, often called castration-resistant disease. Results from the ongoing, international, open-label, phase 2 TRITON2 trial indicated that rucaparib (Rubraca) has antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration, along with a manageable safety profile consistent with that reported in other solid tumor types.. BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. 1-6 Tumors in up to 30 . Parker et al. Rucaparib is thought to work by targeting key proteins (PARP) involved in the DNA repair process. 2. NCT03413995. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Participation eligibility. Strata Trial to Identify Genetically Selected Patients Eligible for Enrollment in Clovis' TRITON Studies in Advanced Prostate Cancer Feb. 1, 2017- Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis' ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which . These 2 novel treatments represent the first approvals in this class of medications for prostate cancer. Strata Oncology will help Clovis Oncology accelerate patient enrollment in ongoing clinical trials assessing Clovis' rucaparib as a treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA or ATM mutations.. Strata is conducting an observational study, the Strata Trial, which provides next-generation sequencing to all advanced cancer patients at affiliated . Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. You take the tablets twice a day, everyday. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells . Newswise — Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known . Rucaparib did not show significant activity in unselected patients with advanced UC regardless of HRD status. These data were presented at ESMO [European Society for Medical Oncology Congress] and subsequently published. Rucaparib is a PARP inhibitor that is being studied for the treatment of mCRPC. The usual treatment for prostate cancer that has spread is chemotherapy and hormone therapy. This trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with metastatic prostate cancer that has become resistant to testosterone-deprivation therapy. Rubraca (rucaparib) is an oral small-molecule inhibitor conditionally approved by the U.S. Food and Drug Administration (FDA) to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry BRCA mutations. Patients will be treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable toxicity and/or as long as the . The findings, published in the Journal of Clinical . It was developed by Clovis Oncology.. Accessed September 21, 2020. Treatment-emergent small cell/NEPC (neuroendocrine prostate cancer) is allowed, but de novo small cell carcinoma of the prostate is excluded. This phase III trial compares the addition of rucaparib to enzalutamide with enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to androgen-deprivation therapy. Rubraca is specifically indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Participation eligibility. . This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the potential of Rubraca ® (rucaparib) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with a BRCA1/2 mutation. The designation, which will expedite the development and review of rucaparib in this setting . 50% Reduction in PSA levels [ Time Frame: Monthly while on treatment; Most patients are expected to be on treatment for approximately 18 months ] First presentation of initial data from Rubraca Phase 2 TRITON2 trial in advanced metastatic castration-resistant prostate cancer (mCRPC) First presentation of genomic profiling data based on tumor tissue and plasma cell free circulating tumor DNA (cfDNA) samples from the TRITON clinical program Additional posters include a subset analysis of the ARIEL3 trial in advanced ovarian cancer and a . Rucaparib is thought to work by targeting key proteins (PARP) involved in the DNA repair process. In this study, they are looking at a drug called rucaparib (or CO-338). The approvals are for the drugs olaparib (Lynparza) and rucaparib (Rubraca). Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. -The prostate cancer indication for this drug is under accelerated approval based on objective response rate and duration of response. NCT04821622. Rucaparib in BRCA-Mutant Metastatic Prostate Cancer: TRITON2 Trial. The approval, specifically for men who previously received an androgen receptor inhibitor and taxane-based chemotherapy, was based . The research will also examine if rucaparib is safe in individuals with metastatic prostate cancer. (1.2, 2.1) The agency set a Prescription Drug User Fee Act (PDUFA) date of May 15, 2020. Rucaparib is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients. By: Joshua Swore Posted: Tuesday, September 8, 2020. All patients had progressed on prior androgen receptor-directed therapy but are chemotherapy naïve. TRITON3 [Rucaparib]: This is an open-label Phase III trial comparing rucaparib with physician's choice of therapy [abiraterone (Zytiga), enzalutamide (Xtandi), or docetaxel] in patients with mCRPC associated with a HRR gene defect. The pharmacokinetic prole of rucaparib in Japanese patients overlapped with that of Western patients. The FDA approved rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.. Histologically confirmed prostate cancer. 2015;26:v69-77. Disease Types: Prostate. Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor. The combination of rucaparib (Rubraca) and enzalutamide (Xtandi) was shown to be safe with early signs of efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 1b RAMP study presented during the 2021 American Association for Cancer Research Virtual Annual Meeting. Prostate cancer . Rucaparib is a PARP inhibitor that is being studied for the treatment of mCRPC by Clovis Oncology. This trial was registered in ClinicalTrials.gov (NCT03397394). . Strata Oncology will help Clovis Oncology accelerate patient enrollment in ongoing clinical trials assessing Clovis' rucaparib as a treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA or ATM mutations.. Strata is conducting an observational study, the Strata Trial, which provides next-generation sequencing to all advanced cancer patients at affiliated . This is a single arm Phase Ib/II, open label, safety, pharmacokinetic and efficacy clinical study in adult patients with metastatic castration-resistant prostate cancer (mCRPC). Rucaparib has not been approved by any regulatory body, including the FDA, for the treatment of patients with prostate cancer. This is a trial of rucaparib, which is another PARP inhibitor. The FDA approvals of olaparib (Lynparza) and rucaparib (Rubraca) for the treatment of men with BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) shifted the paradigm away from sequential antiandrogen therapy with enzalutamide (Xtandi) and abiraterone acetate (Zytiga), said Tanya Dorff, MD, who added that genetic and genomic testing should be considered a key step in the . You have treatment for as long as it is working and the side effects aren't too bad. They also compare the different FDA approvals for both of these medications and outline the safety of this class of drugs in prostate cancer. On May 15, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib (Rubraca ®) for patients with deleterious BRCA mutation (germline or somatic)-associated, metastatic, castration-resistant prostate cancer (mCRPC) who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy. Key Takeaways: This study suggests rucaparib 600 mg taken twice daily had a manageable safety prole for Japanese patients with advanced solid tumors, including ovarian, prostate, endometrial, and pancreatic cancer. on may 15, 2020, the food and drug administration granted accelerated approval to rucaparib (rubraca, clovis oncology, inc.) for patients with deleterious brca mutation (germline and/or. The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is approved in the US for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic BRCA1 or BRCA2 (BRCA) alteration. Available at: Alleghany , Blacksburg , Roanoke , Salem , Wytheville. The accelerated approval of rucaparib, another PARP inhibitor, was based on the TRITON 2 trial, a phase II study that demonstrated an objective response rate (ORR) of 43.5% with rucaparib, with a . But now the accelerated approval will bring a sea change to the prostate cancer space, while stressing the importance of genetic testing for men with high-risk and metastatic disease, according to Alan Bryce, MD. But sometimes this stops working, so doctors want to improve treatment. May 21, 2020. Key efficacy end points were objective response rate (ORR; per RECIST/Prostate Cancer Clinical Trials Working Group 3 in patients with measurable disease as assessed by blinded, independent radiology review and by investigators) and locally Prior research studies have shown that drugs like rucaparib can be of benefit to patients with advanced metastatic prostate cancer who are resistant to androgen deprivation therapy AND who carry a mutation in a DNA repair gene. Rucaparib, Niraparib) gained approval for different clinical settings in ovarian cancer and for BRCA-mutated breast, pancreatic and prostate cancer . 1 The doublet of the PARP inhibitor rucaparib and the androgen . Progressive metastatic prostate cancer despite castrate levels of testosterone (< 50 ng/dL). The FDA granted priority review to rucaparib (Rubraca) for the treatment of adult patients with BRCA1/2 -mutant recurrent, metastatic castration-resistant prostate cancer (mCRPC), according to Clovis Oncology, the drug's manufacturer. BRCA1 or BRCA2 ( BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP-ribose) polymerase inhibitors. Review results from the TRITON2 clinical trial that demonstrated durability with Rubraca® (rucaparib) and anti-tumor efficacy. Nivolumab plus rucaparib demonstrated activity among men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of cohort A2 of the CheckMate 9KD trial. The trial drug rucaparib is a tablet. Ann Oncol. Metastatic castration-resistant prostate cancer is a heterogeneous disease with poor outcomes. The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor—directed therapy and taxane-based chemotherapy.. The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib. The safety profile was consistent with that observed in patients with ovarian or prostate cancer. 3619 - Preliminary results from TRITON2: a phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations 1-6 Tumors in up to 30 . The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib verses treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. Rucaparib Prostate Cancer Approval Sets Stage for Further Research. 1. Co-administration of rucaparib can increase the systemic exposure of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates, which may increase the risk of toxicities of these drugs. To evaluate overall survival (OS) in nonmetastatic hormone-sensitive prostrate cancer patients treated with rucaparib. Until the recent FDA approval of rucaparib (Rubraca) for BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC), this patient population had no biomarker-driven therapies. The aim of this research is to find out if the study drug rucaparib leads to lowering of PSA levels in men with metastatic prostate cancer that has not yet been treated with androgen deprivation therapy (also referred to as metastatic hormone sensitive prostate cancer) and who have an inherited mutation in a gene involved in repairing DNA damage. The international, open-label TRITON2 trial assessed rucaparib for treatment of men with metastatic castration-resistant prostate cancer and a deleterious alteration in a DNA-damage response gene . It added, "RUCAPARIB is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2, and 3 used as a monotherapy and in conjunction with other anti-cancer agents in several tumour forms, including ovarian and prostate cancers.